Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Brain Metastases: early-phase trial registry
41 of 68 indexed Brain Metastases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #203 of 28,707 conditions by registered trial count.
68 US clinical trials · 41 currently recruiting · #203 of 28,707 conditions by registered trial count
Brain Metastases: 68 US clinical trials tracked, 41 recruiting.
Brain Metastases is the subject of 68 registered US clinical trials on ClinicalTrials.gov, 41 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 48 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition brain-metastases
OPEN 41 | RECR 60% | LATE 3 | EARLY 48 | RANK #203 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Opioid Use Disorder (60% recruiting · 258 trials)
Brain Metastases lists 41 open slots (60% of 68 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Brain Metastases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Brain Metastases is recruiting above its size-band peers.
41 of 68 indexed trials (60.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Brain Metastases trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 7 of 68 trials (10.3%). 45 distinct sponsors appear on at least one study for this condition label.
-
Most Brain Metastases trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 68 trials that report a genuine target (sentinel values excluded). 53 of those (77.9%) plan for fewer than 100 participants.
-
Brain Metastases research is mostly interventional.
62 interventional and 6 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
68 total, page 1 of 2
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
Universitaire Ziekenhuizen KU Leuven
NCT04654975
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
M.D. Anderson Cancer Center
NCT06649058
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
NCT05124912
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Canadian Cancer Trials Group
NCT03550391
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
University of Alabama at Birmingham
NCT06857006
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
University of Chicago
NCT02747303
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
M.D. Anderson Cancer Center
NCT07053033
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
NCT05700721
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Memorial Sloan Kettering Cancer Center
NCT05559853
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
NCT05064280
Neurocognitive Decline in Patients With Brain Metastases
University of Texas Southwestern Medical Center
NCT03508752
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
NCT05419076
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Wake Forest University Health Sciences
NCT05692635
Development of MRF for Characterization of Brain Tumors After Radiotherapy
Case Comprehensive Cancer Center
NCT06101069
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
NCT06712927
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Joshua Palmer
NCT05987644
Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
Medical University of South Carolina
NCT07227610
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
Medical College of Wisconsin
NCT05045950
Stereotactic Radiosurgery Dose Escalation for Brain Metastases
University of Utah
NCT02390518
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
Vanderbilt-Ingram Cancer Center
NCT05996432
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Baptist Health South Florida
NCT06048094
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Baptist Health South Florida
NCT05789589
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
University of Texas Southwestern Medical Center
NCT07139990
Phase I Study of Fractionated Stereotactic Radiation Therapy
Albert Einstein College of Medicine
NCT03726359
NTS-WBRT in Brain Metastases
Massachusetts General Hospital
NCT05013892
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Weill Medical College of Cornell University
NCT03449238
MeDex: No Perioperative Dexamethasone in Brain Metastases
University of Louisville
NCT07044557
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
University of Utah
NCT06194929
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
NCT04923542
Evaluation of the CONVIVO System
Dartmouth-Hitchcock Medical Center
NCT05139277
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
M.D. Anderson Cancer Center
NCT05673928
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03223922
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Baptist Health South Florida
NCT04689048
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
Weill Medical College of Cornell University
NCT06072807
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
University of Missouri-Columbia
NCT07175077
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
University of Arizona
NCT06055790
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
University of California, Davis
NCT05452005
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
NCT05048212
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Baptist Health South Florida
NCT05554302
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
M.D. Anderson Cancer Center
NCT06015295
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
UNC Lineberger Comprehensive Cancer Center
NCT04073966
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies
NCT04365374
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
Dana-Farber Cancer Institute
NCT03075072
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
NCT02886585
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
Dana-Farber Cancer Institute
NCT03391362
Preop fSRS for Resectable Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
NCT05267587
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Carey Anders, M.D.
NCT05323955
MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases
Duke University
NCT04246879
Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Cedars-Sinai Medical Center
NCT03163368
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 26 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Brain Metastases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Brain Metastases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Brain Metastases page
68 registered trials, 41 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 41 Brain Metastases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Brain Metastases trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Metastases condition card totals 68 registered trials; most-linked intervention Stereotactic Radiosurgery; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.